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Summary 
Plasmodium vivax and the related simian malarial parasite  P. knowlesi use the DuffT blood group 
antigen as a receptor to invade human erythrocytes and region II of the parasite  ligands  for 
binding to this erythrocyte receptor.  Here,  we identify the peptide within the Duffy blood 
group antigen of human and rhesus  erythrocytes to which the P.  vivax and P.  knowlesi ligands 
bind. Peptides from the NH2-terminal extracellular region of the Duffy antigen were tested for 
their ability to block the binding of erythrocytes to transfected Cos cells expressing on their 
surface region II of the Duffy-binding ligands.  The binding site on the human Duffy antigen 
used by both the P. vivax and P. knowlesi ligands maps to a 35-amino acid region. A 34-amino 
acid peptide from the equivalent region of the rhesus Duffy antigen blocked the binding of 
P.  vivax to human erythrocytes, although the P.  vivax ligand expressed on Cos cells does not 
bind rhesus erythrocytes. The binding of the rhesus peptide, but not the rhesus erythrocyte, to 
the  P.  vivax ligand was explained by interference of carbohydrate with the binding process. 
Rhesus erythrocytes, treated with N-glycanase, bound specifically to P.  vivax region II. Thus, 
the interaction of P.  vivax ligand with human and rhesus erythrocytes appears  to be mediated 
by a peptide-peptide interaction. Glycosylation of the rhesus Duffy antigen appears  to block 
binding of the P. vivax ligand to rhesus erythrocytes. 
I 
nvasion of erythrocytes by  Plasmodium  merozoites is  a 
multistep process that requires a series of specific molec- 
ular interactions between the invading merozoite and the 
target erythrocyte. P.  vivax and the related simian malarial 
parasite, P. knowlesi, require interaction with the erythrocyte 
chemokine receptor, also known as the Duffy blood group 
antigen, to invade human erythrocytes (1-5).  Duffy-nega- 
tive human erythrocytes, which lack the Duffy blood group 
antigen, are completely resistant to invasion by these para- 
sites. Although P.  knowlesi is absolutely dependent on the 
Duffy blood group antigen for invasion of human erythro- 
cytes, P.  knowlesi can efficiently invade rhesus erythrocytes 
by Duffy antigen-independent pathways (4). The erythro- 
cyte receptors for P. knowlesi involved in these Duffy antigen- 
independent invasion pathways are not known. 
The  P.  vivax  and  P.  knowlesi ligands  that bind  to  the 
Duffy blood group antigen contain a cysteine-rich domain 
that occurs in a superfamily of Plasmodium proteins that serve 
as host-binding ligands  (6). These include ligands that bind 
erythrocytes during invasion (7,  8),  as well as ligands that 
mediate binding of P. falciparum-infected erythrocytes to the 
endothelium (6, 9, 10). This cysteine-rich domain, referred 
to  as region II, is found in the Duffy-binding proteins of 
P. vivax and P. knowlesi (the ti gene), in other erythrocyte- 
binding proteins of P.  knowlesi (the [3 and y  genes),  and in 
the P. falciparum  glycophorin A-binding protein EBA-175 
(11). When expressed  in Cos cells, region II in the Duffy- 
binding ligands  of P.  vivax  and  P.  knowlesi binds  human 
Duffy-positive erythrocytes with the same specificity as the 
protein from which it derives (7). 
In this paper, we identify the epitope in the Duffy blood 
group  antigen  that  blocks  the  binding  of Duffy-positive 
human erythrocytes to P. vivax region II that is expressed on 
the surface of Cos cells. Sequence analysis suggests that the 
human and rhesus Duffy antigens contain multiple trans- 
membrane stretches with an ~64-amino acid hydrophilic 
region at the NH2 terminus that is extracellular (12). Here, 
we demonstrate that a 35-amino acid peptide from this ex- 
tracellular portion of the human Duffy blood group antigen 
blocks the binding ofDuffy-positive erythrocytes to region 
II of the Duffy-binding proteins of P. vivax and P. knowlesi. 
We find that the same region of the rhesus Duffy antigen 
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human  erythrocytes,  although  rhesus  erythrocytes  do  not 
bind to P. vivax region II. Rhesus erythrocytes, however, can 
bind  P.  vivax  region  II  after  treatment  with  N-glycanase, 
which  removes  N-linked  sugars,  indicating that  carbohy- 
drates block the receptor on rhesus erythrocytes for P.  viva,~c. 
These studies suggest that the P. vivax ligand can bind the pep- 
tide backbones of both the human and rhesus Duffy antigens. 
Materials  and Methods 
Recombinant Plasmids  for Surface Expression its Cos7 Cells.  The plas- 
mid constructs used to  express region II of the P.  vivax Dully- 
binding protein (pHVDP,22), the P. knowlesi Dully-binding pro- 
tein (pHKADP,22), the P. knowlesi [3 protein (pHKBDR22), and 
P. falciparum  EBA-175  (EBA-175  RII)  on  the  Cos  cell surface 
have been described previously (7,  8).  Each  of these constructs 
contains  DNA  sequences  encoding  region  II  of the  parasite 
ligands fused with the signal sequence  and transmembrane seg- 
ment of herpes simplex virus glycoprotein D  (HSV gD). The fu- 
sion proteins are targeted to the Cos cell surface by the signal se- 
quence  of HSV  gD  and  are  anchored  to  the  surface  by  the 
transmembrane  segment.  These  expression  plasmids  contain  a 
SV40 origin of replication that allows replication in Cos7 cells, as 
well as a Rous sarcoma virus long terminal repeat that serves as a 
promoter for expression in Cos7 cells (13). 
Cell Culture and Tra,4~ection of Cos7 Cells.  Cos7  cells (CRL  1651; 
American Type Culture  Collection, Rockville, MD)  were  cul- 
tured  in  DMEM  with  10%  heat-inactivated FCS  (both  from 
GIBCO BP,  L, Gaithersburg, MD) in a humidified CO2 (5%) in- 
cubator at 37~  Fresh monolayers of Cos7 cells were transfected 
in 3.5-cm-diameter wells with 5 txg ofplasmid DNA by the cal- 
cium  phosphate  precipitation method,  as  described earlier (7). 
Cells were washed three times in PBS 12-16 h after transfection. 
Transfection  efficiencies were  determined  by  inmmnofluores- 
cence  assays 48-60  h  after transfection,  as described earlier (7). 
Ascites containing the n~b  DL6  (kindly provided by Drs.  Gary 
Cohen and Roselyn Eisenberg, University of Pennsylvania, Phil- 
adelphia, PA) that reacts against amino acids 272-279  of the ma- 
ture HSV gD protein were used as the primary antibody in the 
inmmnofluorescence assays as described earlier (13). 
Erythrocyte-binding  Assays.  Cos7 cells were transfected in 3.5- 
cm-diam wells and used for erythrocyte-binding assays 40-60 h 
after transfection, as described earlier (7). Briefly, 100/xl of a 10% 
erythrocyte suspension  was  added to  0.9  ml  of media in wells 
containing transfected cells.  The plates were swirled to nfix the 
erythrocytes well, and the erythrocytes were allowed to settle tbr 
2 h at 37~  Nonadherent erythrocytes were removed by wash- 
ing the Cos7 cells three times with PBS, and the number oftrans- 
fected Cos7  cells with rosettes of erythrocytes was scored in 20 
fields at a magnification of 40 using an inverted microscope. 
To  study the ability of peptides froln the Duffy antigen to 
inhibit erythrocyte binding, transfected Cos cells were preincu- 
bated for 1 h in a 5% CO  2 incubator at 37~  in 0.9 ml of com- 
plete DMEM with 10% FCS containing different concentrations 
(0-100 ixM) of peptides. Human or rhesus  erythrocytes (100  txl) 
at a hematocrit of 10% were added to wells containing different 
concentrations of the peptides and were allowed to bind for 2 h at 
37~  in a 5% CO 2 incubator. Nonadherent erythrocytes were re- 
moved by washing the Cos7 cells three times with PBS, and the 
number of rosettes was scored in 20 fields viewed at a magnifica- 
tion of 40() using an inverted nficroscope. Inhibition curves were 
drawn for three independent experiments and used to determine 
concentrations for 50% inhibition. 
To  study  the  ability of the  chemokine  MGSA  (melanoma 
growth-stimulating activity) in  inhibiting binding,  erythrocytes 
were preincubated in media containing different concentrations 
of MGSA (0-1,000 nM) for 1 h at room temperature before they 
were used in erythrocyte-binding assays, as described earlier (7). 
Erythrocytes and Pretreatments witll Enzymes.  Blood was collected 
in  10%  citrate phosphate  dextrose  (Baxter,  Deerfield,  IL)  and 
stored at 4~  for up to 4 wk.  Standard blood banking methods 
using two  antisera  (anti-Fya and anti-Fyb) were  used to  deter- 
mine the Duffy phenotypes. Duffy-positive erythrocytes used in 
the  binding  assays had  the  Fy(a+b  +)  phenotype.  Erythrocytes 
were washed three times in RPMI 1640  (GIBCO BP,  L) and re- 
suspended to a hematocrit of 10% in RPM[  1640  for use in the 
erythrocyte-binding assays. Washed human  and rhesus  erythro- 
cytes were treated with neuraminidase, as described earlier (14). 
Human, rhesus,  and squirrel monkey erythrocytes were deglyco- 
sylated with the N-glycanase peptide-N-glycosidase F from Fla- 
vobacterium me, ingosepticum (Oxford Glycosystems,  Oxford, U.K.). 
Washed erythrocytes (10(I ~1)  were  incubated with  mixing for 
1 h at 37~  in 500 I*1 of PBS containing 10 U  of N-glycanase and 
reaction buffer supplied by the  manufacturer.  The  erythrocytes 
were washed extensively in PBS to remove the enzyme and stop 
the deglycosylation. 
Pepticle Synthesis.  Peptides  were  synthesized using  an  auto- 
mated synthesizer, as described earlier (15).  Mass  spectrophoto- 
metric  and  analytical reverse-phase  HPLC  analyses  and  amino 
acid composition were performed to confirm the purity and se- 
quence of the synthetic peptides. In some cases, protein sequence 
analysis was also performed to check the sequence of the peptides. 
Results  and Discussion 
Region  II,  the  5'  cysteine-rich region  of the  P.  vivax 
Duffy antigen-binding protein, has been shown  to possess 
erythrocyte-binding properties  (7).  Transfected  Cos  cells 
expressing P. vivax region II on the cell surface bind Duff-y- 
positive, but  not  Duffy-negative, human  erythrocytes (7). 
Here, we have used the Cos cell-binding assay to identify 
the binding site on the human Duffy antigen that is used in 
this interaction. A  35-amino acid peptide (HPEP35)  from 
the NH2-terminal extracellular domain of the human i)uffT 
antigen (Fig. 1 a) was tested for its ability to inhibit binding 
of P. vivax region II to human erythrocytes in the Cos cell- 
binding assay. HPEP35  was chosen because it is recognized 
by anti-Fy6 (Chaudhuri, A., unpublished data), an mAb to 
the human Dully antigen that can block erythrocyte inva- 
sion by P. vivax in vitro (16). To test the ability of HPEP35 
to inhibit binding of human  erythrocytes to  P.  vivax region 
II, Cos cell-binding assays were performed in the presence of 
increasing  concentrations  ((i)-100  b~M) of HPEP35.  Fig.  2 
shows  the  inhibition  curve  from  one  such  experiment. 
HPEP35  inhibits  the  binding  of  Duffy-positive  human 
erythrocytes to Cos cells expressing P.  vivax region II with 
50% inhibition at a concentration of 2.9  -+  /.4 txM (Table 1). 
Three  smaller peptides  from  the  35-anfino  acid  region  of 
HPEP35  were also tested in the inhibition assays (Fig.  1 b). 
The smaller peptides (HPEP13,  HPEP22,  and HPEP3850) 
had  no  effect on  the binding of human  erythrocytes to re- 
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RHPEP34 
AELSPSTENSSQLDFEDVWNSSYGVNDSFPDGDYD 
AELSPSTQNSSQL_NSDLWNFSYDGNDSFPDVDYD 
b  HPEP35  AEL  SPSTENSSQLDFEDVWNS SYGVNDSF  PDGDYD 
HPEPI  3  AELSPSTENSSQL 
H  PE  P22  DFEDVWNS  SYGVNDS  F  PDGDYD 
HPEP3850  PSTENSSQLDFEDVWNS SYGVNDS 
Figure 1.  Peptides from the NH2-terminal, extracellular  segment of  the 
human and rhesus Duffy blood group antigens. (b) Amino acid sequence 
ofpeptides from the human Duffy antigen (HPEP35, HPEP13, HPEP22, 
and HPEP3850). (a) Comparison of the rhesus peptide RHPEP34  and 
the human peptide HPEP35. 
gion II of the P.  vivax protein at concentrations up  to  100 
b~M. HPEP35  also inhibits the binding of human  erythro- 
cytes to region II of the P.  knowlesi Duffy antigen-binding 
protein with 50% inhibition at a concentration of 4.9  +  2.3 
~M. It thus appears that the P. vivax and P. knowlesi ligands 
bind the same site on the human  Duffy blood group  anti- 
gen.  In  addition,  HPEP35  also  inhibits  the  binding  of 
rhesus erythrocytes to region II of the P. knowlesi Duffy an- 
tigen-binding  protein  (the  ot  gene),  suggesting  that  the 
same site within the parasite domain is used for binding to 
both human and rhesus Duffy blood group antigens. 
To rule out the possibility that the inhibition of binding 
observed with  HPEP35  is  a  nonspecific  effect,  we  tested 
the  ability of HPEP35  to  inhibit the  binding of erythro- 
cytes to region II of P. falciparum EBA-175 and region II of 
the P.  knowlesi f3 protein, neither of which binds the Duffy 
antigen. Region II of EBA-175 binds sialic acid residues in 
the  context  of the  glycophorin A  peptide backbone,  and 
region II of the P. knowlesi [3 protein binds an as-yet-uniden- 
tified receptor on rhesus erythrocytes. HPEP35  had no ef- 
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Figure 2.  Inhibition oferythrocyte binding to P. vivax region II with 
the peptide HPEP35. An inhibition curve for one experiment in which 
the peptide HPEP35 is used to inhibit the binding of Duffy-positive hu- 
man erythrocytes to transfected Cos cells expressing P. vivax region II is 
shown. The concentration for 50% inhibition of erythrocyte binding was 
determined for each experiment from the inhibition curve as shown. 
Table 1.  Inhibition of Erythrocyte Binding to Transfected Cos 
Cells Expressing Region H Using Peptides  fiom the Human 
(HPEP35) and Rhesus  (RHPEP34) Duffy Antigens* 
50% inhibition 
concentration 
Region II expressed  (No. of 
on Cos cell surface  Erythrocytes  Mean _+ SD  studies) 
A  Inhibition oferythrocyte binding with HPEP35 
P. vivax  Human Fy(a+b  +)  2.9 -4- 1.4 I~M  (3) 
P. knowlesi oL  Human Fy(a+b  +)  4.1  •  2.7 b~M  (3) 
P. knowlesi (x  Rhesus  13.1  -  6.0 ~M  (3) 
P. knowlesi f3  Rhesus  >100 IxM  (2) 
P. falciparum 
EBA-175  Human Fy(a+b  +)  >100 I~M  (2) 
B  Inhibition oferythrocyte binding with RHPEP34 
P. vivax  Human Fy(a+b  +)  2.1  -  2.1  I.LM  (3) 
P. knowlesi eL  Human Fy(a+b  +)  5.5  -+ 3.9 b~M  (3) 
P. knowlesi (x  Rhesus  4.9 +  2.3 ~M  (3) 
P. knowlesi f3  Rhesus  >100 I,,tM  (2) 
P. falciparum 
EBA-175  Human Fy(a+b  +)  >100 [,*M  (2) 
*Average concentrations  (-+ SD) for the peptides HPEP35  (Fig. 1 b) 
and RHPEP34 (Fig. 1 a) at which 50%} inhibition of  binding is achieved 
are shown.  Inhibition  curves from  two to three  independent  experi- 
ments were used to determine the average concentrations at which 50% 
inhibition is achieved. The highest concentration at which the peptides 
were tested was 100  t~M. For cases where the average concentrations 
for 5{)% inhibition is reported as >100 p~M, the inhibition was <5% at 
the highest peptide concentration used (100 IxM). Numbers in brackets 
(No. of studies) show the number of independent  experiments used for 
the determination of the 50% inhibition concentrations. 
fect on the binding of human  erythrocytes to region II of 
EBA-175 or the binding of rhesus erythrocytes to region II 
of the P. knowlesi [3 protein at concentrations up to 100 btM 
(Table 1). 
The  amino  acid  differences  between  the  human  and 
rhesus Duffy antigens in the 35-amino acid region that has 
been  identified as the binding site are shown  in  Fig.  1  a. 
Compared  with  the  human  Duffy  antigen,  eight  amino 
acid substitutions and a single amino acid deletion are evi- 
dent in the rhesus  sequence  in this region  (17).  To  deter- 
mine whether the corresponding 34-amino acid region of 
the rhesus Duffy antigen (RHPEP34)  serves as the binding 
site for the  P.  knowlesi Duffy antigen-binding protein, the 
ability of RHPEP34  to inhibit erythrocyte binding in Cos 
cell assays was tested (Table 1 B). RHPEP34  inhibits bind- 
ing of rhesus  as well as human  erythrocytes to  region  II 
of  the  P.  knowlesi  Duffy-binding  protein,  indicating  that 
RHPEP34  indeed serves as the binding site on  the  rhesus 
Duffy antigen for the P. knowlesi ligand. As a test for speci- 
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to Region II of the P. vivax Duffy-binding  Ligand* 
Erythrocytes  Treatment  Binding 
Rhesus  None  - 
Rhesus  N:glycanase  + 
Rhesus  Neuraminidase  - 
Squirrel monkey  None 
Squirrel monkey  N-glycanase  + 
Human Fy(a+b +)  None  + 
Human Fy(a+b +)  N-glycanase  + 
Human Fy(a-b  )  None 
Human Fy(a-b-)  N-glycanase  - 
*Transfected Cos cells expressing region II of the P. vivax Duffy-bind- 
ing ligand were tested for binding to rhesus and human erythrocytes. 
Binding is reported as negative (-) when no rosettes were seen in the 
entire well. Where binding is reported as positive (+), ~100-200 ro- 
settes are seen in 20 fields viewed at a magnification of  40. In each case, 
immunofluorescence assays were perfomaed to ensure that P. vivax re- 
gion I1 was expressed on the Cos cell surface. Transfection efficiencies 
were in the range of 2-5%. 
ficity, we  confirmed  that  1LHPEP34  does  not inhibit  the 
binding of human erythrocytes to region II of P. falciparum 
EBA-175 or the binding of rhesus  erythrocytes to region 
II of the  P.  knowlesi [3 protein,  neither of which binds the 
Duffy antigen  (Table  1  /3). We  also  tested  the  ability  of 
R,  HPEP34 to inhibit the binding of human erythrocytes to 
region  II  of the  P.  vivax  Duffy antigen-binding  protein. 
Since P.  vivax region II does not bind rhesus erythrocytes, 
we  expected  that  R,  HPEP34,  a  peptide  from  the  rhesus 
Duff-y  antigen,  would  not  inhibit  the  binding  of human 
erythrocytes to P. vivax region II. Unexpectedly, we found 
that RHPEP34 inhibits the binding of human Duffy-posi- 
tive erythrocytes to P.  vivax region II with 50% inhibition 
at  concentrations  of 2.1  -+  2.1  I~M  (Table  1  B).  Thus,  it 
appears  that  although  P.  vivax region  II does  not bind  the 
Duffy  antigen  on  rhesus  erythrocytes,  a  peptide  from  the 
rhesus Duffy antigen can block the binding of human eryth- 
rocytes to P. vivax region II. 
One  possible  reason  for this  anomalous  result  with  the 
synthetic  peptide  is  that  carbohydrates  on the  rhesus,  but 
not the human,  Duffy blood group antigen may block ac- 
cess  of the  parasite  ligand  to the  peptide  backbone  of the 
receptor  molecule.  It has been demonstrated  that  the  hu- 
man Duffy blood group antigen has asparagine-linked  gly- 
cosylation  (18,  19).  Presumably,  the  rhesus  Duffy antigen 
also  has  asparagine-linked  glycosylation,  since  it  contains 
the  same  amino  acid  sequence  signals  NXS/T  as  the  hu- 
man sequence (17). To determine whether glycosylation of 
the  rhesus  Duffy blood  group  antigen  influences  binding, 
we studied the binding of normal and N-glycanase-treated 
rhesus  erythrocytes to P.  vivax region  II. Whereas  normal 
Table 3.  Inhibition by MGSA of the Attachment  of 
N-Glycanase--treated Rhesus Erythrocytes to Region 1I qf the 
P. vivax Duffy-binding  Ligand* 
Region II  50% inhibition 
expressed on  concentration 
Cos cell surface  Erythrocytes  Treatment  (MGSA) 
P. knowlesi oL  Rhesus  None  5 nM 
P. vivax  Rhesus  N-glycanase  5 nM, 6 nM 
P. knowlesi f3  Rhesus  N-glycanase  >1  IxM 
*Normal and  N--glycanase-treated rhesus erythrocytes were preincu- 
bated with different concentrations (0, 0.1, 1, 10, 100, and 1,000 nM) 
of the chemokine MGSA (melanoma growth~timulating  activity) and 
used in binding assays with transfected Cos cells expressing P. vivax re- 
gion II. Numbers represent concentrations at which 50% inhibition of 
binding was achieved. Two separate experiments were performed with 
P. vivax region II and N-glycanase-treated rhesus erythrocytes. 
rhesus erythrocytes do not bind P.  vivax region II, N-gly- 
canase-treated rhesus  erythrocytes bind the P.  vivax ligand 
(Table  2).  This  indicates  that,  despite  the  differences  in 
amino acid sequences,  P.  vivax can bind the peptide back- 
bones of both the  human and rhesus  Duffy antigens.  This 
explains why P,  HPEP34, a peptide derived from the rhesus 
Duffy antigen,  inhibits  the binding of human erythrocytes 
to P. vivax region II. 
Erythrocytes  from  a  new  world  monkey,  the  squirrel 
monkey (Saimiri sciureus),  do not bind the  P.  vivax Duffy- 
binding protein (5),  although they express the Duffy blood 
group antigen (16,  17). We found that the squirrel monkey 
erythrocytes fail to bind to Cos cells  expressing P. vivax re- 
gion II, but do bind to Cos cells  expressing the P.  knowlesi 
Duffy binding protein (oL gene) region II (7).  N-glycanase- 
treated  squirrel  monkey erythrocytes,  like  rhesus  erythro- 
cytes, bind to Cos cells expressing P. vivax region II (Table 2), 
indicating that carbohydrates on the Duffy blood group an- 
tigen of squirrel monkey erythrocytes also block its binding 
to the P. vivax Duffy-binding protein. 
It can be argued that enzymatic treatment with N-glyca- 
nase reduces the negative surface charge density on erythro- 
cytes and leads to nonspecific binding interactions. Another 
possibility that must be considered is that N-glycanase treat- 
ment may create  a  novel binding  epitope  independent  of 
the  Duffy blood group antigen.  To  test these  possibilities, 
the  following  experiments  were  performed.  Since  sialic 
acid  residues  are  the  most  important  source  of negative 
charge  on  the  erythrocyte  surface,  neuraminidase-treated 
rhesus  erythrocytes were tested for binding to P.  vivax re- 
gion II. Neuraminidase-treated  rhesus erythrocytes did not 
bind P.  vivax region II (Table  2).  In the same experiment, 
neuraminidase-treated  human erythrocytes did not bind re- 
gion II of EBA-175, which requires sialic  acid for binding, 
indicating  that  sialic  acid was  removed from the  erythro- 
cytes. Reduction of negative charge on the surface cannot, 
therefore,  account for the  binding  of N-glycanase-treated 
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that  N-glycanase-treated, Duffy-negative human  erythro- 
cytes do not bind P.  vivax region II  (Table 2).  This rules 
out the possibility that N-glycanase treatment may create a 
novel epitope that binds P. vivax region II. 
We have previously shown that the chemokine, MGSA, 
binds the Duffy blood group antigen and can be used to in- 
hibit the binding ofP. vivax region II to Duff-y-positive hu- 
man erythrocytes (3, 7). MGSA also binds the rhesus Duffy 
antigen (Horuk, R., unpublished data).  Indeed, MGSA in- 
hibits  the binding  of rhesus  erythrocytes to  Cos  cells  ex- 
pressing region  II  of the  P.  knowlesi Duffy-binding ligand 
(the (x gene; Table 3).  To confirm that P.  vivax region II 
binds  the  peptide  backbone  of the  deglycosylated rhesus 
Duffy  blood  group  antigen,  we  tested  whether  MGSA 
could  inhibit  the  binding  of N-glycanase-treated  rhesus 
erythrocytes to P. vivax region II. MGSA inhibits the bind- 
ing of N-glycanase--treated rhesus erythrocytes to region II 
of the  P.  vivax Duffy antigen-b,  inding protein, with  50% 
inhibition at nanomolar concentrations (Table 3).  Inhibition 
of erythrocyte binding indicates that MGSA and  P.  vivax 
region II bind the same  molecule on N-glycanase-treated 
rhesus  erythrocytes, namely the deglycosylated rhesus  Duffy 
antigen.  Chemokine and the  P.  vivax Duffy-binding pro- 
tein, however, do not recognize the same epitope because 
the 35 met from the human Duffy antigen does not block 
binding of chemokines to human erythrocytes (Horuk, P,., 
unpublished data). 
One puzzle is why P.  vivax infects squirrel monkeys, al- 
though squirrel monkey erythrocytes do not bind P.  vivax 
Duffy-binding protein (5) and also do not bind to Cos cells 
expressing P.  vivax region II (this  study). Squirrel monkey 
erythrocytes do contain the reticulocyte receptor to which 
the P.  vivax reticulocyte-binding proteins bind (20).  Bind- 
ing to the reticulocyte receptors is responsible for the pref- 
erential invasion ofreticulocytes by P. vivax (20). These in- 
teractions  are  not,  however,  sufficient  for  invasion.  For 
example, Duffy-negative human erythrocytes that carry the 
reticulocyte receptor are not invaded by P.  vivax.  We can 
speculate that  the  Duffy blood group  antigen  on squirrel 
monkey erythrocytes, despite  not being ideal for binding 
because of carbohydrate modifications, still function in in- 
vasion.  The  erythrocyte-binding assays used  may not  be 
sensitive  enough  to  detect  this  weaker  interaction.  How 
does one then explain the refractoriness of rhesus erythro- 
cytes to invasion by P.  vivax when P.  vivax region II binds 
N-glycanase-treated rhesus erythrocytes? Rhesus erythrocytes 
are known to lack the reticulocyte receptor (20)  for the 
P.  vivax  reticulocyte-binding proteins.  It  is  possible  that, 
like the Duffy antigen, the reticulocyte receptor is also ab- 
solutely required for invasion. Their absence on rhesus eryth- 
rocytes may be the reason for their refractoriness to P. vivax. 
Differences  exist  between  the  nature  of the  receptor- 
binding specificities for region II of P. falciparum  EBA-175 
and of the P.  vivax Duffy-binding ligand. Whereas P. falci- 
parum  EBA-175  requires both  sialic  acid and  the  peptide 
backbone  of glycophorin A  (8,  14),  the  P.  vivax  Duffy- 
binding ligand requires only the peptide backbone of the 
Duffy blood group antigen. Both tryptic fragments of gly- 
cophorin A containing amino acids 1-64 and the 35-amino 
acid synthetic peptide from the extracellular domain of the 
Duffy antigen inhibit binding of erythrocytes to  their re- 
spective ligands  with  50%  inhibition  at  concentrations of 
",5  I,~M (reference 8,  and  this paper).  Thus,  peptides de- 
rived from the Duffy antigen (in the absence of any carbo- 
hydrates) appear to  effectively inhibit erythrocyte binding 
by the  P.  vivax  ligand.  Furthermore,  rhesus  erythrocytes 
can bind  P.  vivax region II  after treatment with N-glyca- 
nase.  We  conclude  that  the  receptor-ligand  interactions 
that mediate  erythrocyte invasion differ in  the protein to 
which they bind and in the requirement for carbohydrate. 
The  receptor for P. falciparum  EBA-175  consists  of both 
carbohydrate and the peptide backbone of glycophorin A; 
the  P.  vivax Duffy-binding ligand  interacts only with the 
peptide backbone of the receptor molecule. 
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